AU2015252518B2 - New stable antibody-drug conjugate, preparation method therefor, and use thereof - Google Patents

New stable antibody-drug conjugate, preparation method therefor, and use thereof Download PDF

Info

Publication number
AU2015252518B2
AU2015252518B2 AU2015252518A AU2015252518A AU2015252518B2 AU 2015252518 B2 AU2015252518 B2 AU 2015252518B2 AU 2015252518 A AU2015252518 A AU 2015252518A AU 2015252518 A AU2015252518 A AU 2015252518A AU 2015252518 B2 AU2015252518 B2 AU 2015252518B2
Authority
AU
Australia
Prior art keywords
group
compound according
compound
oct
ligase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015252518A
Other languages
English (en)
Other versions
AU2015252518A2 (en
AU2015252518A1 (en
Inventor
Leilei Chen
Lu Jiang
Cao LV
Gang Qin
Lili Shi
Chubing Tan
Jinduo YUAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genequantum Healthcare Suzhou Co Ltd
Original Assignee
Genequantum Healthcare Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genequantum Healthcare Suzhou Co Ltd filed Critical Genequantum Healthcare Suzhou Co Ltd
Publication of AU2015252518A2 publication Critical patent/AU2015252518A2/en
Publication of AU2015252518A1 publication Critical patent/AU2015252518A1/en
Application granted granted Critical
Publication of AU2015252518B2 publication Critical patent/AU2015252518B2/en
Priority to AU2020200975A priority Critical patent/AU2020200975B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2015252518A 2014-04-29 2015-04-29 New stable antibody-drug conjugate, preparation method therefor, and use thereof Active AU2015252518B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020200975A AU2020200975B2 (en) 2014-04-29 2020-02-11 New stable antibody-drug conjugate, preparation method therefor, and use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410174890.8 2014-04-29
CN201410174890 2014-04-29
PCT/CN2015/077887 WO2015165413A1 (zh) 2014-04-29 2015-04-29 一种新型的稳定型抗体药物耦联物及其制备方法和用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020200975A Division AU2020200975B2 (en) 2014-04-29 2020-02-11 New stable antibody-drug conjugate, preparation method therefor, and use thereof

Publications (3)

Publication Number Publication Date
AU2015252518A2 AU2015252518A2 (en) 2016-12-15
AU2015252518A1 AU2015252518A1 (en) 2016-12-15
AU2015252518B2 true AU2015252518B2 (en) 2019-11-14

Family

ID=54358190

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015252518A Active AU2015252518B2 (en) 2014-04-29 2015-04-29 New stable antibody-drug conjugate, preparation method therefor, and use thereof
AU2020200975A Active AU2020200975B2 (en) 2014-04-29 2020-02-11 New stable antibody-drug conjugate, preparation method therefor, and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020200975A Active AU2020200975B2 (en) 2014-04-29 2020-02-11 New stable antibody-drug conjugate, preparation method therefor, and use thereof

Country Status (8)

Country Link
US (5) US11040084B2 (OSRAM)
EP (2) EP3517114A1 (OSRAM)
JP (2) JP6666264B2 (OSRAM)
KR (1) KR102511249B1 (OSRAM)
CN (2) CN106856656B (OSRAM)
AU (2) AU2015252518B2 (OSRAM)
ES (1) ES2736505T3 (OSRAM)
WO (1) WO2015165413A1 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3517114A1 (en) 2014-04-29 2019-07-31 Genequantum Healthcare (Suzhou) Co., Ltd. New stable antibody-drug conjugate, preparation method and use thereof
KR102590454B1 (ko) 2016-07-07 2023-10-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Ｈｅｒ２を標的とする免疫結合体
WO2021136475A1 (en) * 2019-12-31 2021-07-08 Genequantum Healthcare (Suzhou) Co., Ltd. A drug conjugate and applications thereof
CN114901694A (zh) * 2019-12-31 2022-08-12 启德医药科技（苏州）有限公司 抗trop2抗体、抗体-药物缀合物及其应用
CN116547000A (zh) * 2020-10-30 2023-08-04 西湖生物医药科技(杭州)有限公司 经修饰的红细胞及其在递送活性剂中的用途
CN115867283A (zh) * 2020-12-23 2023-03-28 启德医药科技（苏州）有限公司 包含开环硫代琥珀酰亚胺基团、寡肽片段和手性部分的新型异构化合物
AU2021423664B2 (en) 2021-01-28 2026-02-05 Genequantum Healthcare (Suzhou) Co., Ltd. Ligase fusion proteins and applications thereof
EP4304661A1 (en) * 2021-03-08 2024-01-17 Genequantum Healthcare (Suzhou) Co., Ltd. Anti-her2 antibody-immune agonist conjugate and applications thereof
CN117042806A (zh) 2021-03-08 2023-11-10 启德医药科技（苏州）有限公司 抗体-免疫激动剂缀合物及其应用
AU2022259314A1 (en) * 2021-04-14 2023-11-30 Genequantum Healthcare (Suzhou) Co., Ltd. Linkers, conjugates and applications thereof
CN117337195A (zh) * 2021-04-29 2024-01-02 上海汇连生物医药有限公司 抗体偶联药物的制备方法及应用
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
EP4444759A4 (en) * 2021-12-09 2025-11-26 Genequantum Healthcare Suzhou Co Ltd ANTIBODY-CYTOKINE FUSION PROTEINS AND THEIR APPLICATIONS
CN118946369A (zh) * 2022-03-29 2024-11-12 启德医药科技（苏州）有限公司 Adc的冷冻干燥工艺
EP4534090A1 (en) 2022-06-02 2025-04-09 Genequantum Healthcare (Suzhou) Co., Ltd. Oligosaccharide linker, linker-supported material comprising oligosaccharide linker, antibody-drug conjugate having sugar chain remodeling, preparation method therefor and use thereof
KR20250068592A (ko) * 2022-06-28 2025-05-16 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. 항-fgfr3 항체 접합체 및 이의 의학적 용도
AU2023296781A1 (en) 2022-07-01 2025-02-13 Genequantum Healthcare (Suzhou) Co., Ltd. Immobilized endoglycosidase fusion protein and use thereof
WO2024012566A2 (en) 2022-07-15 2024-01-18 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody, linkers, payload, conjugates and applications thereof
EP4554956A1 (en) * 2022-07-15 2025-05-21 Genequantum Healthcare (Suzhou) Co., Ltd. Linkers, conjugates and applications thereof
WO2024041587A1 (zh) 2022-08-25 2024-02-29 启德医药科技（苏州）有限公司 抗体偶联药物的药物组合物
KR20250084935A (ko) * 2022-10-14 2025-06-11 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. 링커-페이로드 화합물, 접합체 및 이의 응용 분야
CN120957726A (zh) * 2023-03-21 2025-11-14 启德医药科技（苏州）有限公司 抗体-药物偶联物与癌症疗法的组合及其用途
KR20250162918A (ko) * 2023-03-30 2025-11-19 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. 부위 특이적 직교 생체접합체 모달리티 및 이의 응용
WO2024213091A1 (en) 2023-04-13 2024-10-17 Genequantum Healthcare (Suzhou) Co., Ltd. Combination of antibody-drug conjugate and anti-pd-1 antibody, and use thereof
WO2025149014A1 (en) 2024-01-12 2025-07-17 Genequantum Healthcare (Suzhou) Co., Ltd. Pharmaceutical composition
WO2025255054A1 (en) * 2024-06-03 2025-12-11 Darbix Llc Methods and compositions for oligonucleotide bioconjugation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3434275A1 (en) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
US7241020B2 (en) * 2003-11-20 2007-07-10 Mirror Lite High definition vehicular mirror
MXPA06014065A (es) * 2004-06-01 2007-01-31 Genentech Inc Conjugados de droga-anticuerpo y metodos.
RU2487877C2 (ru) * 2008-04-30 2013-07-20 Иммьюноджен, Инк. Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры)
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
RU2661083C2 (ru) * 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
GB2529356B (en) * 2013-04-28 2020-12-23 Genequantum Healthcare Co Ltd Novel linkers, coupling intermediates, conjugates, preparation method and application thereof
EP3517114A1 (en) 2014-04-29 2019-07-31 Genequantum Healthcare (Suzhou) Co., Ltd. New stable antibody-drug conjugate, preparation method and use thereof
CN107828351B (zh) 2016-09-15 2021-07-27 E·I·内穆尔杜邦公司 用于粘合的导电糊料
EP3821005A4 (en) 2018-07-09 2022-10-26 Genequantum Healthcare (Suzhou) Co., Ltd. AGAINST TROPHOBLAST ANTIGEN 2 (TROP2) SPECIFIC ANTIBODIES
CN114901694A (zh) 2019-12-31 2022-08-12 启德医药科技（苏州）有限公司 抗trop2抗体、抗体-药物缀合物及其应用
AU2021423664B2 (en) 2021-01-28 2026-02-05 Genequantum Healthcare (Suzhou) Co., Ltd. Ligase fusion proteins and applications thereof
KR102942648B1 (ko) 2021-02-09 2026-03-20 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. 결합 장치 및 결합 화합물을 생성하는 방법
CN117042806A (zh) 2021-03-08 2023-11-10 启德医药科技（苏州）有限公司 抗体-免疫激动剂缀合物及其应用
AU2022259314A1 (en) 2021-04-14 2023-11-30 Genequantum Healthcare (Suzhou) Co., Ltd. Linkers, conjugates and applications thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BEN-QUAN SHEN ET AL, "Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates", NATURE BIOTECHNOLOGY, (2012-01-22), vol. 30, no. 2, doi:10.1038/nbt.2108, ISSN 1087-0156, pages 184 - 189 *

Also Published As

Publication number Publication date
ES2736505T3 (es) 2020-01-02
AU2020200975B2 (en) 2021-01-28
JP6666264B2 (ja) 2020-03-13
EP3517114A1 (en) 2019-07-31
US11911434B2 (en) 2024-02-27
US20240165192A1 (en) 2024-05-23
CN112999362A (zh) 2021-06-22
CN112999362B (zh) 2023-11-14
US20240156894A1 (en) 2024-05-16
AU2015252518A2 (en) 2016-12-15
US20210177929A1 (en) 2021-06-17
US20170112944A1 (en) 2017-04-27
KR102511249B1 (ko) 2023-03-20
WO2015165413A1 (zh) 2015-11-05
AU2015252518A1 (en) 2016-12-15
CN106856656A (zh) 2017-06-16
US20210401924A1 (en) 2021-12-30
KR20170020328A (ko) 2017-02-22
AU2020200975A1 (en) 2020-02-27
JP2017514812A (ja) 2017-06-08
EP3138568A4 (en) 2017-12-13
WO2015165413A8 (zh) 2016-04-14
EP3138568B1 (en) 2019-04-17
JP2020055828A (ja) 2020-04-09
US11911435B2 (en) 2024-02-27
CN106856656B (zh) 2021-01-26
JP7100617B2 (ja) 2022-07-13
US11040084B2 (en) 2021-06-22
EP3138568A1 (en) 2017-03-08

Similar Documents

Publication Publication Date Title
US20240165192A1 (en) Stable antibody-drug conjugate, preparation method therefor, and use thereof
US12269902B2 (en) Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
AU608531B2 (en) Advanced anticancer therapy and cytotoxic medicaments for its implementation
CN115175917A (zh) 药物缀合物及其应用
Eccles et al. Regression of Established Breast Carcinoma Xenografts with Antibody-directed Enzyme Prodrug Therapy against c-erb B2 p185
US7311892B2 (en) Multidrug multiligand conjugates for targeted drug delivery
CN109152845A (zh) 含有在环内包含至少两个(-ch2-ch2-o-)单元的接头的缀合物和缀合试剂
Masheta et al. Improving antitumor targeting via using PL3 homing peptide and cell-penetrating peptide
JP2026004883A (ja) コンジュゲートおよびその用途
Hofmann Conditional Cell Penetration of a Masked CPP and Optimization of Multimeric CPP-Delivery Modules for Intracellular Cargo Delivery
BR112018010535B1 (pt) Compostos peptídicos e conjugados peptídicos para o tratamento de câncer por quimioterapia com mediação por um receptor

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 NOV 2016

FGA Letters patent sealed or granted (standard patent)